Prime Success Responds to Sinovac Biotech's False and Misleading Claims

Prime Success L.P., an 8% shareholder of Sinovac Biotech (SVA), has issued a letter criticizing Sinovac's board (1Globe Activist Board) for allegedly distorting facts ahead of the July 8, 2025 special meeting. Prime Success argues the current board is prioritizing litigation over long-term success, deliberately timed a dividend distribution date to influence the vote, and misrepresented Prime Success's contributions to the company's success with CoronaVac. Prime Success urges shareholders to support a board nominated by SAIF Partners IV L.P. to break the pattern of conflict and prioritize future dividends.

Analysis

Sinovac Biotech Ltd. (SVA) faces a significant governance challenge from Prime Success L.P., an 8% shareholder, which has publicly criticized the incumbent '1Globe Activist Board' for alleged distortions and mismanagement ahead of a special shareholder meeting scheduled for July 8, 2025. Prime Success contends that the current board is prioritizing extensive litigation over Sinovac's long-term strategic success and has deliberately timed a dividend distribution for one day after the special meeting, potentially to influence shareholder voting. Furthermore, Prime Success highlights its pivotal past investment, alongside Vivo Capital, which it claims enabled the development of CoronaVac, leading to substantial revenues and the current potential for dividend distributions—a contribution Prime Success feels the incumbent board has misrepresented. The activist shareholder advocates for a new board slate nominated by SAIF Partners IV L.P., arguing this would usher in experienced governance focused on operational stability and consistent dividend payouts for all shareholders. This public dispute, underscored by a moderately negative sentiment score for SVA (-0.6) and a market impact score of 0.6, signals considerable uncertainty surrounding the company's leadership, strategic direction, and approach to capital returns, with the upcoming meeting being a critical determinant of its future.

Key Decisions for Investors

• Investors should closely monitor all communications and developments related to the Sinovac special shareholder meeting on July 8, 2025, as the outcome of the board election will significantly impact company governance and strategy.
• Carefully scrutinize proxy materials from both Prime Success/SAIF Partners and the incumbent '1Globe Activist Board' to assess the arguments regarding future dividend policies, litigation strategy, and overall management approach before casting votes.
• Acknowledge the heightened risk profile and potential for increased share price volatility for SVA due to this ongoing activist campaign, the board dispute, and associated litigation, and consider portfolio adjustments reflecting this uncertainty.